[89Zr]Zr-Df-SA-BioDAC

[89Zr]Zr-Df-SA-BioDAC is a preclinical radiopharmaceutical candidate designed for the molecular imaging of prostate cancer using positron emission tomography (PET). The agent is a dimeric aptamer complex (DAC) that specifically targets prostate-specific membrane antigen (PSMA), a protein highly expressed in most prostate cancer cells. Structurally, the complex consists of a PSMA-binding dimeric aptamer that is biotinylated (BioDAC) and conjugated to streptavidin (SA). This assembly is then chelated with deferoxamine (Df) to facilitate labeling with the radioisotope zirconium-89 (89Zr). While preclinical studies in murine models confirmed selective tumor uptake, the current iteration demonstrated high renal retention attributed to the streptavidin component, suggesting a need for structural optimization before clinical advancement.

Other names

89Zr-labeled anti-PSMA dimeric aptamer89Zr-Df-SA-BioDAC